COVID-19 & Psoriasis Resource Center

Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy.

J Eur Acad Dermatol Venereol. 2020 Jul 31;:

Authors: Talamonti M, Galluzzo M, Chiricozzi A, Quaglino P, Fabbrocini G, Gisondi P, Marzano AV, Potenza C, Conti A, Parodi A, Belloni Fortina A, Bardazzi F, Argenziano G, Rongioletti F, Stingeni L, Micali G, Loconsole F, Venturini M, Bongiorno MR, Feliciani C, Rubegni P, Amerio P, Fargnoli MC, Pigatto P, Savoia P, Nisticò SP, Giustini S, Carugno A, Cannavò SP, Rech G, Prignano F, Offidani A, Lombardo M, Zalaudek I, Bianchi L, Peris K, PSO-BIO-COVID study group

Abstract
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, is creating an unprecedented global public health emergency with the continuous growth of infected individuals worldwide. Italy was one of the first European country to face the first wave of infection outside mainland China. The first case of COVID-19 was confirmed in Lombardy on February 20th , 2020, and subsequently, a rapid increase in the number of detected cases was observed, spreading through Italy and the rest of Europe.3 As of April 22nd , confirmed COVID-19 cases in Italy were 183,957.

PMID: 32735716 [PubMed - as supplied by publisher]